Front Range Biosciences Strikes Deal with Hemp Trading to Distribute First THC-Free Hemp Variety Panakeia
Ryan Allway
December 22nd, 2019
News
LAFAYETTE, Colo., Dec. 18, 2019 /PRNewswire/ — Front Range Biosciences® (“FRB”), an agricultural technology company focused on breeding and nursery production of new plant varieties and seeds for the hemp and coffee industries, today announced its agreement with Spanish company Hemp Trading to distribute Panakeia, the first THC-free and high CBG (18%) content hemp variety. This alliance will enable the large-scale production and distribution of Panakeia in the American market.
This latest advancement in hemp plant science was developed in tandem with Spanish university Universidad Politécnica de Valencia. Panakeia’s unique properties of being completely free of the psychoactive component THC and high in cannabigerol (CBG), a non-psychoactive cannabinoid, can be effectively leveraged by both the American agricultural and wellness industries.
Farmers that grow the Panakeia hemp variety will no longer have to worry if their hemp is going to rise above 0.3% THC limit because this variety consistently comes in at 0.00%, which presents lucrative opportunities for harvest and later commercialization. CBG is an interesting minor cannabinoid which has been implicated in several areas of human health and wellness.
“The American market is key to the commercialization of Panakeia as hemp is grown here on a large scale, and the agreement with these three companies represents a big opportunity for launching Panakeia in the USA,” says Ernesto Llosá, CEO of Hemp Trading. “The crop forecasts for next year are more than promising. It is expected that production will triple from 80,000 acres in 2019 to around 250,000 acres in 2020.”
“Introducing a cutting edge plant variety like Panakeia will have a seismic ripple effect in the hemp farming industry in the US,” said Dr. Jonathan Vaught, Co-founder and CEO of Front Range Biosciences. “Our company’s mission from the beginning has been to provide sustainable and modern solutions to mainstream agricultural practices, and I believe the Panakeia hemp variety will not only encourage more streamlined farming methods, but also introduce more Americans to even more of the potential wellness properties of the hemp plant.”
About Front Range Biosciences
Front Range Biosciences is an agricultural biotech company that specializes in tissue culture propagation and breeding of high-value crops at industrial scale to improve consistency and efficiency for clone and seed production. FRB developed the first Clean Stock® program for cannabis and hemp and has an advanced breeding program for identifying and improving commercially relevant traits. FRB has global reach through facilities in Colorado, California and Wisconsin, and a partnership with the Center for Research in Agricultural Genomics in Barcelona, Spain. FRB’s Clean Stock program provides a consistent supply of disease and pathogen-free plants to farmers and data-driven breeding solutions for creating new varieties of hemp, coffee, and young plants and seeds. FRB’s technology has been consistently recognized as an industry standard and was the inaugural winner of MJBizDaily’s Hemp Game Changer Award. FRB is located in Lafayette, Colorado.
Media Contact
Rosie Mattio
MATTIO Communications
frb@mattio.com
SOURCE Front Range Biosciences
This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.
About Ryan Allway
Mr. Allway has over a decade of experience in the financial markets as both a private investor and financial journalist. He has been actively involved in the cannabis industry since its inception, covering public and private companies.
Search CannabisFN
Press Coverage
Psychedelics Index
Top Videos
Matthew Nordgren is an ambitious executive, dedicated philanthropist, and accomplished athlete who brings a unique passion to creating strategic alliances. He has breadth and depth of experience in finance, corporate development, and capital sourcing, as well as in building highly motivated teams of skilled professionals. In 2005, Mr. Nordgren received his education at the University […]
Alan Brochstein’s 420 Investor is the go-to community for investors to learn, explore, and profit from the marijuana companies. The main goal of 420 Investor is to provide real-time, objective information about the top marijuana companies in the market in order to help investors capitalize on cannabis.
EuroMed Therapeutics is building the ninth Israeli licensed producer to capitalize on the domestic medical marijuana market and Europe’s nascent export market — worth upwards of $66 billion.
MichiCann Medical Inc. owns or controls 11 medical cannabis dispensaries in Michigan and is in the final stages to acquire another 11 shops, as well as three indoor cultivation facilities in the state.
Network Partners
About CFN Media Group
CFN Enterprises Inc. (OTCQB: CNFN) owns and operates CFN Media Group, the premier agency and financial media network reaching executives, entrepreneurs and consumers worldwide. Through its proprietary content creation, video library, and distribution via www.CannabisFN.com, CFN has built an extensive database of cannabis interest, assisting many of the world’s largest cannabis firms and CBD brands to build awareness and thrive. For more information, please visit www.cfnenterprisesinc.com.
Disclaimer: Matters discussed on this website contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time-to-time have a position in the securities mentioned herein and will increase or decrease such positions without notice. The Information contains forward-looking statements, i.e. statements or discussions that constitute predictions, expectations, beliefs, plans, estimates, or projections as indicated by such words as "expects", "will", "anticipates", and "estimates"; therefore, you should proceed with extreme caution in relying upon such statements and conduct a full investigation of the Information and the Profiled Issuer as well as any such forward-looking statements. Any forward looking statements we make in the Information are limited to the time period in which they are made, and we do not undertake to update forward looking statements that may change at any time; The Information is presented only as a brief "snapshot" of the Profiled Issuer and should only be used, at most, and if at all, as a starting point for you to conduct a thorough investigation of the Profiled Issuer and its securities and to consult your financial, legal or other adviser(s) and avail yourself of the filings and information that may be accessed at www.sec.gov, www.pinksheets.com, www.otcmarkets.com or other electronic sources, including: (a) reviewing SEC periodic reports (Forms 10-Q and 10-K), reports of material events (Form 8-K), insider reports (Forms 3, 4, 5 and Schedule 13D); (b) reviewing Information and Disclosure Statements and unaudited financial reports filed with the Pink Sheets or www.otcmarkets.com; (c) obtaining and reviewing publicly available information contained in commonlyknown search engines such as Google; and (d) consulting investment guides at www.sec.gov and www.finra.com. You should always be cognizant that the Profiled Issuers may not be current in their reporting obligations with the SEC and OTCMarkets and/or have negative signs at www.otcmarkets.com (See section below titled "Risks Related to the Profiled Issuers, which provides additional information pertaining thereto). For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity-based compensation in the companies it writes about, or a combination of the two. For full disclosure, please visit: https://www.cannabisfn.com/legal-disclaimer/. A short time after we acquire the securities of the foregoing company, we may publish the (favorable) information about the issuer referenced above advising others, including you, to purchase; and while doing so, we may sell the securities we acquired. In addition, a third-party shareholder compensating us may sell his or her shares of the issuer while we are publishing favorable information about the issuer. Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time to time have a position in the securities mentioned herein and will increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity- based compensation in the companies it writes about, or a combination of the two. For full disclosure please visit: https://www.cannabisfn.com/legal-disclaimer/.
Copyright © Accelerize Inc. · All Rights Reserved · Privacy Policy · Legal Disclaimer
